Arch Therapeutics Inc is a pioneering medical device company that prioritizes patient health and safety. With an unwavering commitment to advancing technology, Arch Therapeutics Inc focuses on developing innovative solutions for surgical and therapeutic applications. The company's corporate philosophy revolves around employing cutting-edge research and development to address unmet needs in the medical field. Arch Therapeutics Inc places great emphasis on collaboration with healthcare professionals, ensuring that their products meet the highest standards of efficacy and performance. With a strong dedication to improving patient outcomes, Arch Therapeutics Inc embodies values of excellence, integrity, and innovation in all aspects of their operations.

Arch Therapeutics Inc is primarily present in the United States. As a biotechnology company, Arch Therapeutics Inc focuses on developing innovative products to address unmet medical needs. With its headquarters located in Framingham, Massachusetts, the company primarily operates within the United States. By leveraging its proprietary self-assembling peptide technology platform, Arch Therapeutics Inc aims to revolutionize the field of wound healing and surgical adhesives. With a strong emphasis on research and development, the company is committed to advancing medical solutions that enhance patient outcomes and drive growth in the healthcare sector.

Arch Therapeutics Inc has achieved several significant milestones in recent years. One notable accomplishment is the completion of successful clinical trials for its flagship product, AC5 Topical Hemostat. This innovative hemostatic device has garnered attention and recognition from the medical community for its ability to rapidly control bleeding in both surgical and trauma settings. Arch Therapeutics Inc has also secured key partnerships and collaborations with leading healthcare organizations, further establishing its position in the market. Additionally, the company has received regulatory approvals and patents, highlighting its commitment to innovation and intellectual property protection. These achievements highlight Arch Therapeutics Inc's dedication to advancing medical solutions and improving patient outcomes.

Arch Therapeutics Inc is a biotechnology company based in the United States. Established in 2006, the company specializes in developing and commercializing novel medical devices. Arch Therapeutics is focused on addressing unmet clinical needs by providing innovative solutions for hemostasis and sealing in surgical and interventional medicine. With its flagship product, AC5 Advanced Wound System, the company aims to revolutionize surgical procedures by improving patient outcomes and reducing healthcare costs. Arch Therapeutics Inc has demonstrated a commitment to research and development, aiming to create groundbreaking healthcare solutions. Their dedication to innovation and advancement makes Arch Therapeutics Inc a prominent player in the biotechnology industry.

The main competitors of Arch Therapeutics Inc in the market include companies like Johnson & Johnson, Baxter International, and Medtronic.

Arch Therapeutics Inc is primarily active in the biotechnology and medical device industries.

The business model of Arch Therapeutics Inc revolves around the development and commercialization of novel wound healing and surgical products. This Massachusetts-based biotechnology company focuses on creating innovative solutions for the management of bleeding and fluid loss during surgical procedures. Arch Therapeutics aims to provide superior surgical tools and technologies to improve patient outcomes and enhance surgical performance. This company's dedication to advancing medical care through its cutting-edge products highlights its commitment to revolutionizing the field of surgical medicine.

De Arch Therapeutics K/W is 0,01.

De Arch Therapeutics KUV is 0,01.

De AlleAktien Kwaliteitsscore voor Arch Therapeutics is 6/10.

De verwachte Arch Therapeutics omzet is 140,76 mln. USD.

De verwachte Arch Therapeutics winst is 112,18 mln. USD.

Arch Therapeutics is a biotechnology company that focuses on the development and marketing of therapeutic solutions for controlling bleeding and tissue formation. The company is headquartered in Framingham, Massachusetts and is listed on the Nasdaq stock exchange under the ticker symbol "ARTH".

Arch Therapeutics keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Arch Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van Arch Therapeutics is US03939W1099.

Het WKN van Arch Therapeutics is A1W2JT.

De ticker van Arch Therapeutics is ARTH.

Binnen de laatste 12 maanden betaalde Arch Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Arch Therapeutics naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Arch Therapeutics is momenteel .

Arch Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Arch Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Arch Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Arch Therapeutics van 21-9-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 21-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 21-9-2024.

In het jaar 2023 heeft Arch Therapeutics 0 USD aan dividenden uitgekeerd.

De dividenden van Arch Therapeutics worden in USD uitgekeerd.